Immunoluminometric assay (ILMA) for intact human proinsulin and its conversion intermediates

Zilkens, T.; Eberle, Ansgar M; Schmidt‐Gayk, H.

doi:10.1016/0009-8981(95)06217-3

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This resulted in lower limits of the insulin concentration being considered as completely suppressed levels and called for the necessity of separate proinsulin assays. 14 Intact proinsulin was measured by an immunoluminometric assay (ILMA) 15 without cross-reaction for insulin.…”

Section: Hormone Assaysmentioning

confidence: 99%

Islet Hyperplasia in Adults: Challenge to Preoperatively Diagnose Non‐Insulinoma Pancreatogenic Hypoglycemia Syndrome

et al. 2006

View full text Add to dashboard Cite

show abstract

Section: Hormone Assaysmentioning

confidence: 99%

Islet Hyperplasia in Adults: Challenge to Preoperatively Diagnose Non‐Insulinoma Pancreatogenic Hypoglycemia Syndrome

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The concentration of proinsulin and the cleavage product is 100-fold lower than that of C-peptide. Consequently, cross-reactivity does not significantly influence C-peptide detection [5,22]. Studies have reported that lispro, aspart or glargine synthetic insulin in the absence of insulin and in the setting of insulin concentrations of 30, 100, 300 and 1000 mIU/L yielded results inferior to the lower limit at all concentrations (<0.20 μU/mL or <1.39 pmol/L) [23].…”

Section: Discussionmentioning

confidence: 99%

Role of a Novel Insulin Resistance Index based on Combined Levels of C-peptide and Insulin in Assessment of the Heterogeneity of Diabetes Mellitus

Dai

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The C-peptide-to-insulin ratio (C/I) is associated with hepatic insulin clearance and insulin resistance. We established a novel C-peptide-to-insulin ratio index (CPIRI) and explored its application in the heterogeneity of non-autoimmune diabetes.Methods A total of 865 adults diagnosed with new-onset diabetes mellitus (DM) within 1 year and 54 healthy controls (HC) were recruited. Our CPIRI model was established with fasting C/I as the independent variable and homeostasis model assessment of insulin resistance (HOMA-IR) as the dependent variable. Patients with negative-autoantibodies against pancreatic islets were subclassified according to CPIRI, age of onset , hemoglobin A1c (HbA1c), body mass index (BMI) and homeostatic model assessment of β-cell function (HOMA-β) via cluster analysis.Results Fasting C/I and HOMA-IR in both diabetic and healthy subjects were hyperbolically correlated, and log(C/I) and log(HOMA-IR) were linearly and negatively correlated; the correlation coefficient was −0.83 (P = 0.000) and −0.76 (P = 0.000), respectively. Finally, we obtained the equations CPIRI(DM) = 670/(C/I) 2.24 + 0.25 and CPIRI(HC) = 670/(C/I) 2.24 − 1 (F = 1904.39, P = 0.000). Pancreatic islet autoantibody-negative patients were further subclassified into three subtypes; subtype 1 (13.8%) had severe insulin resistance, subtype 2 (42.1%) suffered elderly-onset DM with slight symptoms, and subtype 3 (44.1%) suffered severe dysfunction of pancreatic islets. Each subtype exhibited different clinical characteristics and complications.Conclusions CPIRI can be used to effectively evaluate insulin resistance. Adult-onset non-autoimmune diabetes can be subclassified into 3 subtypes according to CPIRI along with other symptom-based characteristics of diabetic progression.

show abstract

Pro-insuline

Chevenne¹

2006

EMC - Biologie Médicale

View full text Add to dashboard Cite

Immunoluminometric assay (ILMA) for intact human proinsulin and its conversion intermediates

Cited by 4 publications

References 31 publications

Islet Hyperplasia in Adults: Challenge to Preoperatively Diagnose Non‐Insulinoma Pancreatogenic Hypoglycemia Syndrome

Islet Hyperplasia in Adults: Challenge to Preoperatively Diagnose Non‐Insulinoma Pancreatogenic Hypoglycemia Syndrome

Role of a Novel Insulin Resistance Index based on Combined Levels of C-peptide and Insulin in Assessment of the Heterogeneity of Diabetes Mellitus

Pro-insuline

Contact Info

Product

Resources

About